Pulmo BioTech, Inc is dedicated to bringing revolutionary medical diagnostic technologies to the market. The company’s current product base is composed of an array of molecular imaging substances developed for the diagnosis of pulmonary embolism, pulmonary hypertension, and lung inflammatory disorders. Presently, these substances are in the process of receiving regulatory approval before entering Phase I human trials.
The company has used the brand name “PulmoBind” for these substances. These products have the potential to completely replace the conventional technology being used for a nuclear medicine-based diagnosis of pulmonary embolism. The substances could also create new markets for the diagnosis of pulmonary hypertension, as well as other disorders of the pulmonary system.
Pulmo BioTech’s staff has extensive experience and a reputation for bringing innovation and entrepreneurial spirit to their projects. The team has proven themselves in both small and large firms, and has worked with a broad range of investment institutions. Their business experience and high academic and medical credentials are a key strength to Pulmo BioTech.
The director and CEO, Garry McCann, has worked within the fields of CAT X-ray generators, medical imaging CCDs and IR Image Sensors. He earned his MBA from Warwick University Business School and a BSc in physics from the University of Surrey. Prior to this position, he was the managing director of NE Technology Ltd, an international leader focused on designing and manufacturing radiation detection equipment.
Let us hear your thoughts: Pulmo BioTech, Inc. Message Board